DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactSector

Technical Analysis of Nippon India Nifty Pharma ETF Units Exchange Traded Fund (BSE:PHARMABEES)

TradingView 13 hrs ago·20 Oct 2026, 5:51 pm

Sector TradingView

Nippon India Nifty Pharma ETF is a fund that tracks the performance of the top pharmaceutical companies listed on the NSE. The fund aims to provide investors with exposure to the Indian pharma sector through a basket of stocks, rather than buying individual company shares.

For investors, this ETF offers a convenient way to diversify their portfolio across the entire pharma sector. It helps reduce the risk associated with investing in a single company while still benefiting from the overall growth potential of the sector.

Investors should monitor the performance of the underlying pharmaceutical stocks and the broader market trends. Keeping an eye on regulatory changes and industry developments will be key to understanding the fund's future performance.